NO970030L - Isolert nukleinsyresekvens som koder for et tumor-rejeksjonsantigen presentert av HLA-A2 - Google Patents
Isolert nukleinsyresekvens som koder for et tumor-rejeksjonsantigen presentert av HLA-A2Info
- Publication number
- NO970030L NO970030L NO970030A NO970030A NO970030L NO 970030 L NO970030 L NO 970030L NO 970030 A NO970030 A NO 970030A NO 970030 A NO970030 A NO 970030A NO 970030 L NO970030 L NO 970030L
- Authority
- NO
- Norway
- Prior art keywords
- hla
- nucleic acid
- tumor rejection
- acid sequence
- sequence encoding
- Prior art date
Links
Classifications
-
- G01N33/5758—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Foreliggende oppfinnelse beskriver nukleinsyremole- kyler som koder for en antigenrejeksjonsforløper. Nærmere bestemt beskrives at tumorrejeksjonsantigenforløperen, eller "TRAP"en, bearbeides til minst ett tumorrejeksjons- antigen som presenteres av HLA-A2-molekyler. Konsekvenser av oppfinnelsen er også angitt.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27235194A | 1994-07-08 | 1994-07-08 | |
| US08/370,319 US5856091A (en) | 1993-03-18 | 1995-01-10 | Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2 |
| PCT/US1995/008153 WO1996001557A1 (en) | 1994-07-08 | 1995-06-27 | Isolated nucleic acid sequence coding for a tumor rejection antigen presented by hla-a2 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO970030L true NO970030L (no) | 1997-01-06 |
| NO970030D0 NO970030D0 (no) | 1997-01-06 |
Family
ID=26955454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO970030A NO970030D0 (no) | 1994-07-08 | 1997-01-06 | Isolert nukleinsyresekvens som koder for et tumor-rejeksjonsantigen presentert av HLA-A2 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US5856091A (no) |
| EP (1) | EP0772626A4 (no) |
| JP (1) | JPH10503928A (no) |
| CN (1) | CN1152251A (no) |
| AU (1) | AU696738B2 (no) |
| CA (1) | CA2194451A1 (no) |
| FI (1) | FI970071A7 (no) |
| NO (1) | NO970030D0 (no) |
| NZ (1) | NZ289616A (no) |
| WO (1) | WO1996001557A1 (no) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5856091A (en) * | 1993-03-18 | 1999-01-05 | Ludwig Institute For Cancer Research | Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2 |
| US6013481A (en) * | 1993-07-22 | 2000-01-11 | Ludwig Institute For Cancer Research | Isolated, nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof |
| US5874560A (en) | 1994-04-22 | 1999-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Melanoma antigens and their use in diagnostic and therapeutic methods |
| WO1995029193A2 (en) | 1994-04-22 | 1995-11-02 | The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services | Melanoma antigens |
| US5821122A (en) * | 1995-06-07 | 1998-10-13 | Inserm (Institute Nat'l De La Sante Et De La Recherche . .) | Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof |
| US5674749A (en) * | 1996-03-26 | 1997-10-07 | Ludwig Institute For Cancer Research | Monoclonal antibodies which bind to tumor rejection antigen precursor melan-A, and uses thereof |
| AU727028B2 (en) * | 1996-06-25 | 2000-11-30 | Ludwig Institute For Cancer Research | Brain glycogen phosphorylase cancer antigen |
| US6080399A (en) | 1998-04-23 | 2000-06-27 | Arch Development Corporation | Vaccine adjuvants for immunotherapy of melanoma |
| WO2008039818A2 (en) | 2006-09-26 | 2008-04-03 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Modified t cell receptors and related materials and methods |
| JP2015533473A (ja) * | 2012-07-12 | 2015-11-26 | ペルシミューン,インコーポレイテッド | 個別のがんワクチン及び適応免疫細胞療法 |
| US10605766B2 (en) * | 2014-07-15 | 2020-03-31 | Illumina, Inc. | Biochemically activated electronic device |
| US10987045B2 (en) | 2015-09-14 | 2021-04-27 | Biosense Webster (Israel) Ltd. | Basket catheter with individual spine control |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3297893A (en) | 1963-09-19 | 1967-01-10 | Litz Co | Brush mechanisms |
| US5487974A (en) * | 1992-12-22 | 1996-01-30 | Ludwig Institute For Cancer-Research | Method for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cells |
| US5856091A (en) * | 1993-03-18 | 1999-01-05 | Ludwig Institute For Cancer Research | Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2 |
| US5620886A (en) | 1993-03-18 | 1997-04-15 | Ludwig Institute For Cancer Research | Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2 |
| US5874560A (en) * | 1994-04-22 | 1999-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Melanoma antigens and their use in diagnostic and therapeutic methods |
-
1995
- 1995-01-10 US US08/370,319 patent/US5856091A/en not_active Expired - Lifetime
- 1995-06-27 FI FI970071A patent/FI970071A7/fi unknown
- 1995-06-27 CN CN95194017A patent/CN1152251A/zh active Pending
- 1995-06-27 CA CA002194451A patent/CA2194451A1/en not_active Abandoned
- 1995-06-27 JP JP8504333A patent/JPH10503928A/ja active Pending
- 1995-06-27 WO PCT/US1995/008153 patent/WO1996001557A1/en not_active Ceased
- 1995-06-27 NZ NZ289616A patent/NZ289616A/en unknown
- 1995-06-27 EP EP95925356A patent/EP0772626A4/en not_active Withdrawn
- 1995-06-27 AU AU29517/95A patent/AU696738B2/en not_active Ceased
-
1997
- 1997-01-06 NO NO970030A patent/NO970030D0/no not_active Application Discontinuation
-
1999
- 1999-01-04 US US09/224,834 patent/US6201111B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP0772626A1 (en) | 1997-05-14 |
| FI970071L (fi) | 1997-01-07 |
| EP0772626A4 (en) | 1997-09-10 |
| US6201111B1 (en) | 2001-03-13 |
| US5856091A (en) | 1999-01-05 |
| AU696738B2 (en) | 1998-09-17 |
| CA2194451A1 (en) | 1996-01-25 |
| WO1996001557A1 (en) | 1996-01-25 |
| FI970071A0 (fi) | 1997-01-07 |
| CN1152251A (zh) | 1997-06-18 |
| NZ289616A (en) | 1997-12-19 |
| FI970071A7 (fi) | 1997-01-07 |
| NO970030D0 (no) | 1997-01-06 |
| JPH10503928A (ja) | 1998-04-14 |
| AU2951795A (en) | 1996-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO953601D0 (no) | Nukleinsyre som koder for en tumorreksjonsantigenforlöper | |
| NO963589L (no) | Beskrivelse av kreftilstander ved MAGE-genuttrykking | |
| DK0948518T3 (da) | Isoleret nucleinsyremolekyle kodende for et cancer-associeret antigen, selve antigenet samt anvendelser deraf | |
| NO970030L (no) | Isolert nukleinsyresekvens som koder for et tumor-rejeksjonsantigen presentert av HLA-A2 | |
| ES2098127T3 (es) | Procedimiento para la purificacion de taxoides. | |
| MX9204661A (es) | Compuestos intermedios derivados de eter y procedimiento para su preparacion. | |
| CY1110695T1 (el) | Μεθοδοι για την δημιουργια υψηλου τιτλου ανευ-βοηθου παρασκευασματων απελευθερωμενων ανασυνδυασμενων aav φορεων | |
| EA200200565A1 (ru) | Применение клеток, трансфицированных днк, кодирующей лиганд мнс класса ii, и способ получения таких клеток | |
| TR200002921T2 (tr) | Yarı-Sentetik ekteinasidinler | |
| FI960268A0 (fi) | Menetelmä sairauden diagnosoimiseksi määrittämällä GAGE-tuumorihyljintäantigeenin prekursorien ilmentymistä | |
| IT8023225A0 (it) | Processo per la separazione di ammoniaca da gas contenenti ammoniaca. | |
| IT8123284A0 (it) | Gas.procedimento per la produzione di | |
| DK0804467T3 (da) | Isolerede, trunkerede nukleinsyremolekyler, som koder for GAGE-tumorafstødningsantigen | |
| DK0614366T3 (da) | Anvendelse af creatinphosphat eller phosphoenolpyrodruesyre til behandling af tumorer | |
| ATE180489T1 (de) | Für leberzellkarzinom spezifisches onkogen | |
| IT8124602A0 (it) | Processo per la preparazione di 1,1-dialo-1,2,2,2-etrafluoroetani. | |
| IT8820117A0 (it) | Procedimento per la preparazione di bis(2,2,6,6_tetrametil_4_piperidil)ammina. | |
| DE3767493D1 (de) | Wanderschichtreaktor zur entfernung von unerwuenschten, gasfoermigen bestandteilen aus gasen. | |
| NO20001404D0 (no) | Nye stereoselektive fremgangsmåter for fremstilling av gabapentinanaloger | |
| ES8703454A1 (es) | Un procedimiento para la preparacion de piridozinilimidazolinonas. | |
| IT8221219A0 (it) | Procedimento per la produzione di alfa-aminoderivati ciclici di 1(3',4'-metilendiossifenil)etanolo . | |
| EP0048532A3 (en) | Sultines; a process for producing these; a process for producing sulfoxides; a process for producing sparsomycin and related compounds | |
| IT7906924V0 (it) | Guarnizione composita per giunti omocineti, particolarmente per la copertura dello spazio che separa la parte conduttrice da quella condotta di detti giunti. | |
| SE8500471L (sv) | Forfarande for uppbyggandet av schaktanleggning for hiss | |
| ATE23336T1 (de) | Verfahren zur herstellung von 3,6bis(carbo|thoxyamino)-2,5-diaziridinyl-1,4benzochinon. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |